№ lp_1_2_45527
File format: docx
Character count: 25385
File size: 171 KB
This document provides technical instructions for the preparation and submission of data files through the EDPass system, aimed at reporting chronic absenteeism data in U.S. schools.
Year:
2023
Region / City:
Washington, DC
Topic:
Chronic Absenteeism
Document Type:
Technical Guide
Institution:
U.S. Department of Education
Author:
Brandon Scott
Target Audience:
State Education Agencies, Local Education Agencies, and Schools
Period of Validity:
SY 2022-23
Approval Date:
March 2023
Revision Date:
August 2023
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2017
Region / City:
Delta State, Nigeria
Topic:
Pay Satisfaction, Tardiness, Absenteeism
Document Type:
Academic Article
Author:
Ezeh Leonard Nnaemeka, Etodike Chukwuemeka Etodike, Ike Precious Rosemary, Okorocha Forstina Chinwe
Target Audience:
Scholars, Researchers, Civil Servants
Period of Effect:
2017
Date of Approval:
30.09.2017
Date of Changes:
N/A
Year:
2023
Region / city:
Australia
Topic:
Chronic hyperkalaemia, kidney disease, sodium zirconium cyclosilicate
Document Type:
Submission to PBAC
Agency / organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target audience:
Medical practitioners, healthcare professionals
Period of validity:
Ongoing, based on PBAC recommendation and PBS listing
Approval date:
1 September 2023
Date of amendments:
Not specified
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Year:
2015
Country:
New Zealand
City:
Wellington
Subject:
Chronic kidney disease
Document type:
National consensus statement
Issuing body:
Ministry of Health
Authors:
CKD Core Work Group
Target audience:
Clinicians and managers in funder and provider organisations
Healthcare setting:
Primary care
Publication date:
March 2015
ISBN:
978-0-478-44476-6
License:
Creative Commons Attribution 4.0 International
Focus population:
Adults with chronic kidney disease
Clinical scope:
Identification, classification, and management of CKD
Period covered:
Contemporary clinical practice as of 2015
Note:
Year
Subject:
Chronic Homelessness
Document Type:
Checklist
Organ / Institution:
HUD
Context:
A checklist for documenting chronic homelessness eligibility, including housing history, disability status, and client certifications.
Year:
2024
Region / City:
United States
Topic:
Medical Appeal Letter
Document Type:
Template
Organization / Institution:
OptiNose, Inc.
Author:
OptiNose, Inc.
Target Audience:
Healthcare providers, medical professionals
Period of Validity:
Indefinite
Approval Date:
05/2024
Date of Changes:
None
Year:
2023
Region / city:
Canberra
Subject:
Chronic Kidney Disease, Pain Management
Document Type:
Guideline
Organization / Institution:
Canberra Health Services
Author:
Unknown
Target Audience:
CHS medical staff
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2017
Region / City:
N/A
Topic:
Nephrology, Anaemia, Chronic Kidney Disease
Document Type:
Patient Information
Organization / Institution:
Nephrology Department
Author:
Emma Head
Target Audience:
Patients with Chronic Kidney Disease
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2026-2029
Region / City:
Scotland
Topic:
Chronic Pain Management
Document Type:
Guidance
Organization:
Scottish Government
Target Audience:
Healthcare professionals, individuals experiencing chronic pain
Implementation Period:
2026-2029
Approval Date:
Not specified
Amendment Date:
Not specified
Context:
A consultation document from the Scottish Government aimed at gathering feedback on recommendations for the management of chronic pain, including medication review, communication, non-pharmacological approaches, and opioid stewardship.
Year:
2026
Region / City:
Not specified
Subject:
Chronic pain management
Document type:
Clinical guidance / Flowchart
Institution:
Healthcare provider / Multidisciplinary team
Target audience:
General practitioners, advanced nurse practitioners, physiotherapists, occupational therapists, pharmacists
Key concepts:
Pain assessment, differential diagnosis, rehabilitation, medication management, referral criteria
Clinical setting:
Outpatient / Primary care
Patient considerations:
Functional deficits, distress, polypharmacy, suspected drug-seeking behaviour
Interventions:
Education, self-management, physiotherapy, occupational therapy, pharmacological review, pain team referral
Year:
2025
Region / City:
Australia
Topic:
Health Care, Chronic Disease Management
Document Type:
Fact Sheet
Organization / Institution:
Australian Government Department of Health
Author:
Australian Government Department of Health
Target Audience:
General practitioners, prescribed medical practitioners, health care providers, patients with chronic conditions
Period of Action:
From 1 July 2025
Approval Date:
22 May 2025
Date of Changes:
1 July 2025
Last updated:
22 May 2025
Effective date:
1 July 2025
Jurisdiction:
Australia
Program:
Medicare Benefits Schedule
Framework name:
Chronic condition management
Document type:
Government factsheet
Responsible body:
Department of Health, Disability and Ageing
Affected providers:
General practitioners, prescribed medical practitioners, allied health professionals
Transition period:
1 July 2025–30 June 2027
Patient eligibility:
Chronic or terminal conditions present or likely to be present for at least 6 months
Fees:
$156.55 (GP), $125.30 (prescribed medical practitioner)
Registration requirement:
MyMedicare
Consultation bodies:
MBS Review Taskforce; General Practice and Primary Care Clinical Committee
Implementation review:
Post-implementation review after approximately two years
Year:
2016
Region / City:
Connecticut
Topic:
Chronic Homelessness Verification
Document Type:
Guide
Organization / Institution:
CT BOS
Author:
Jane Doe
Target Audience:
CoC Program Participants, Housing Agencies
Period of Validity:
N/A
Approval Date:
01/12/2016
Modification Date:
N/A
Year:
2024
Region / City:
Australia
Theme:
Pharmaceutical benefits, Chronic myeloid leukaemia (CML) treatment
Document type:
Research analysis
Organization / Institution:
Drug Utilisation Sub-Committee (DUSC)
Author:
Drug Utilisation Sub-Committee (DUSC)
Target audience:
Healthcare professionals, policymakers, pharmaceutical industry
Period of validity:
From March 2022 onward
Approval date:
October 2024
Date of changes:
March 2022
Year:
2023
Region / City:
England
Topic:
Healthcare, Quality Standards
Document Type:
Policy document
Organization / Institution:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Target Audience:
Healthcare providers, Medical professionals
Period of Validity:
2023-2024
Approval Date:
01/04/2023
Date of Amendments:
01/08/2023
Contextual Description:
Policy document outlining business rules for COPD management under the Quality and Outcomes Framework for NHS England.
Year:
2023/2024
Region / city:
NHS England
Topic:
Healthcare, Quality and Outcomes Framework (QOF)
Document type:
Business rules, Technical specification
Organization / institution:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Target audience:
General practitioners, GP system suppliers
Period of validity:
2023–2024
Approval date:
01/04/2023
Amendment date:
01/04/2024
Description:
This document provides the technical business rules and dataset specifications for Chronic Kidney Disease (CKD) under the Quality and Outcomes Framework (QOF) for use by NHS England and General Practice Systems.